PharmaShots Weekly Snapshots (November 14 – November 17, 2023)
This week PharmaShots’ news was all about the updates on regulatory, M&A pharma, and Clinical Trials . Check out our full report below:
AstraZeneca’s Imfinzi + CT Received NMPA Approval for the treatment of Locally Advanced/metastatic Biliary Tract Cancer
Read More: AstraZeneca
Roche received the EU’s CHMP Positive Opinion for the approval of subcutaneous injection of Tecentriq
Read More: Roche
BMS Receives the US FDA’s Approval for Augtyro (repotrectinib) to Treat Non-Small Cell Lung Cancer (NSCLC)
Read More: BMS
The European Commission Approved argenx’s Vyvgart with Halozyme’s Enhanze for the Treatment of Generalized Myasthenia Gravis
Read More: argenx & Halozyme
Praxis Precision's elsunersen has been awarded the PRIME (PRIority MEdicines) designation by the European Medicines Agency (EMA) for the treatment of SCN2A developmental and epileptic encephalopathy (SCN2A-DEE)
Read More: Praxis Precision
Ajinomoto to acquire Forge Biologics for $620M
Read More: Ajinomoto & Forge Biologics
For ~$175 million, Astellas acquires Propella Therapeutics
Read More: Astellas & Propella Therapeutics
The US FDA Approved Cormedix’s DefenCath for the Reduction of Catheter-Related Bloodstream Infections (CRBSI) In Adult Hemodialysis Patients
Read More: Cormedix
For ~$180 million, GTCR to Acquire Cloudbreak Health
Read More: GTCR
Q32 Bio Re-Acquires the Rights to Bempikibart (ADX-914) for Autoimmune Diseases from Amgen
Read More: Q32 Bio
Intercept Pharmaceutical highlights the P-II trial results for OCA + Bezafibrate to treat PBC-Induced Liver Damage
Read More: Intercept Pharmaceutical
Kite (Gilead) Expands its Collaboration Agreement with Arcellx for CART-DdBCMA to Treat Multiple Myeloma
Read More: Kite & Arcellx
New data presented at AHA 2023 for zodasiran by Arrowhead
Read More: Arrowhead
New data presented at AHA 2023 for plozasiran by Arrowhead
Read More: Arrowhead
Vertex and CRISPR Therapeutics Received Conditional Marketing Authorization for Casgevy by the United Kingdom MHRA to Treat Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Read More: Vertex & CRISPR Therapeutics
Tonix Pharmaceuticals Highlights the P-III Trial Results of TNX-102 SL for the Management of Fibromyalgia
Read More: Tonix Pharmaceuticals
SpringWorks Therapeutics Highlights the P-IIb Trial Results for Mirdametinib to Treat Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN)
Read More: SpringWorks Therapeutics
AbbVie Publishes the P-III Trial Results for Ubrelvy (ubrogepant) as Treatment for Migraine in ‘The Lancet’
Read More: AbbVie
Related Post:- PharmaShots Weekly Snapshots (November 06–10, 2023)
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.